Clinical trial
ET3-201: Phase 1 Study of Hematopoietic Stem Cell Transplantation (HSCT) Gene Therapy Incorporating a Lentiviral Vector (LV) Encoding a High Expressing Factor VIII Transgene for Treatment of Severe Hemophilia A
NCT04418414 is registered in ClinicalTrials.gov with Expression Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ET3-201: Phase 1 Study of Hematopoietic Stem Cell Transplantation (HSCT) Gene Therapy Incorporating a Lentiviral Vector (LV) Encoding a High Expressing Factor VIII Transgene for Treatment of Severe Hemophilia A
- Lead sponsor
- Expression Therapeutics, LLC
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- September 1, 2024
- Completion date
- August 31, 2039
- Enrollment
- 7 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.